Subsequent CAR-T and engineered antibody for relapsed/refractory…
For multiple myeloma patients who've already tried one CAR-T therapy, switching to a different target appears significantly more effective than repeating the same approach.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
EIF4A3-dependent nonsense-mediated decay buffers AML1-ETO9a dosage…
A protein marker that suppresses a dangerous leukemia variant predicts better survival in certain acute myeloid leukemia patients, offering hope for more tailored treatment decisions.
NONEBlood biomarkers predict conversion from cognitively stable to mild…
A blood test combining three types of damage markers can identify Down syndrome adults at high risk for Alzheimer's disease years before memory problems emerge, enabling earlier intervention attempts.
NONECombining genome-wide polygenic scores with registry data for…
People with genetic risk factors develop colon cancer roughly a decade earlier than average, suggesting genetic screening could enable earlier and more personalized cancer prevention strategies.
NONETargeting nuclear export and Janus Kinase/Signal Transducer and…
A two-drug combination targeting disease pathways simultaneously shows promise for myelofibrosis by restoring tumor-suppressing proteins and reducing inflammatory signals in early testing.